FIELD: biotechnology.
SUBSTANCE: invention relates to the use of a chimeric antigen receptor (CAR) therapy for CD19, containing a population of immune effector cells expressing CAR for CD19, for the treatment of cancer in a subject in combination with a PD–1 inhibitor. Also a method of treating a subject having cancer, comprising administering to the subject a CD19 CAR therapy and a PD-1 inhibitor is disclosed.
EFFECT: invention is effective for the treatment of cancer.
95 cl, 14 dwg, 8 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
Authors
Dates
2023-12-07—Published
2017-07-28—Filed